ASND Ascendis Pharma A/S
Price Chart
Executive Summary
Ascendis Pharma reported Q1 2026 revenue of €246.6M (+144% YoY), driven by YORVIPATH sales tripling to €196.9M. Operating profit turned positive to €24.8M vs a loss of €104.2M, and net profit of €629.3M included a €679.0M deferred tax asset recognition. Subsequent events include FDA approval of YUVIWEL and a $187.5M PRV sale, strengthening the balance sheet.
Actionable Insight
The strong YORVIPATH growth and positive operating income signal a fundamental inflection point. Monitor Q2 2026 for initial YUVIWEL revenue and the PRV sale proceeds, which will further strengthen liquidity. The convertible note conversion eliminates $575M in debt, potentially improving equity quality.
Key Facts
- Revenue €246.6M, up 144% YoY (Q1 2025: €100.95M)
- Operating profit €24.8M vs loss of €104.2M YoY
- Net profit €629.3M (includes €679.0M deferred tax asset recognition)
- Basic EPS €10.20 vs -€1.58 YoY
- YORVIPATH revenue €196.9M, up 341% YoY
- Cash and cash equivalents €572.8M at March 31, 2026
- YUVIWEL (navepegritide) FDA approval for achondroplasia in February 2026
- Agreement to sell Rare Pediatric Disease PRV for $187.5M on May 6, 2026
- Completed conversion of $575M convertible notes into equity on May 6, 2026
Financial Impact
Revenue increased by €145.6M YoY; operating profit improved by €129.0M; net profit includes €679.0M non-cash deferred tax benefit
Risk Factors
- BioMarin patent litigation (ITC trial ongoing) could impact YUVIWEL commercialization
- Foreign exchange headwinds (USD/EUR volatility) may affect reported revenue
- Uncertainty around tariff measures on pharmaceutical products
- Sustained profitability depends on continued commercial execution for YORVIPATH and YUVIWEL
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001612042-26-000005 |
| Document: 0001612042-26-000005-index-headers.html | 0001612042-26-000005 |
| Document: 0001612042-26-000005-index.html | 0001612042-26-000005 |
| Document: 0001612042-26-000005.txt | 0001612042-26-000005 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
Insider Cluster
| $216.79 $218.84 | ▲ +0.95% | ▲ +0.55% | $205.81 (−5.06%) |
|
May 19, 2026
21d ago
|
ANALYST-UPGRADE
| $237.98 $241.34 | ▲ +1.41% | ▲ +0.37% | $205.81 (−13.52%) |
|
May 16, 2026
24d ago
|
ANALYST-UPGRADE
| $170.74 $162.84 | ▼ −4.63% | ▼ −3.78% | $205.81 (+20.54%) |
|
May 7, 2026
4w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $205.81 (−16.38%) |
|
May 7, 2026
4w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $205.81 (−16.38%) |
|
May 6, 2026
4w ago
|
Press Release
| $246.14 $246.14 | · 0.00% | ▼ −0.83% | $205.81 (−16.38%) |
|
Apr 21, 2026
7w ago
|
6-K
| $240.29 $231.05 | ▼ −3.85% | ▼ −4.86% | $205.81 (−14.35%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $242.95 $244.48 | ▲ +0.63% | ▼ −0.58% | $205.81 (−15.29%) |
|
Apr 8, 2026
8w ago
|
6-K
| $241.71 $239.28 | ▼ −1.01% | ▼ −0.94% | $205.81 (−14.85%) |
|
Apr 8, 2026
8w ago
|
6-K
| $241.71 $239.28 | ▼ −1.01% | ▼ −0.94% | $205.81 (−14.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access